Eli Lilly's tirzepatide cuts heart failure risks, company says – NBC News

By
Internationalfinancialnews.com
-
0
152


  1. Eli Lilly’s tirzepatide cuts heart failure risks, company says  NBC News
  2. Eli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study  CNBC
  3. Live news: Eli Lilly’s weight loss drug cuts the risk of heart failure in latest trial  Financial Times
  4. Eli Lilly says tirzepatide showed positive results in late-stage trial evaluating it as treatment for heart failure  MarketWatch
  5. Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity  Investors | Eli Lilly and Company


LEAVE A REPLY

Please enter your comment!
Please enter your name here